Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

501. Amisulpride for schizophrenia. Full Text available with Trip Pro

Amisulpride for schizophrenia. The treatment of schizophrenia with old, 'typical' antipsychotic drugs such as haloperidol can be problematic, because many people treated with these drugs will suffer from movement disorders. Amisulpride is said to be an "atypical" antipsychotic which induces less movement disorder and which is effective for the negative symptoms of schizophrenia.To evaluate the effects of amisulpride as compared with placebo, typical and atypical antipsychotic drugs (...) for schizophrenia.The authors carried out electronic searches of Biological Abstracts (1982-1999), CINAHL (1982-1999), Cochrane Library (Issue 4, 1999), Cochrane Schizophrenia Group's Register (November 2000), EMBASE (1980-1999), LILACS(1982-1999), MEDLINE (1966-1999) and PsycLIT (1974-1999). They checked all identified studies for further trial citations, and sought these studies in the Science Citation Index. They also contacted authors of trials and the manufacturer of amisulpride.All randomised controlled

2002 Cochrane

502. Antidepressants for people with both schizophrenia and depression. Full Text available with Trip Pro

Antidepressants for people with both schizophrenia and depression. Depressive symptoms, often of substantial severity, are found in 50% of newly diagnosed suffers of schizophrenia and 33% of people with chronic schizophrenia who have relapsed. Depression is associated with dysphoria, disability, reduction of motivation to accomplish tasks and the activities of daily living, an increased duration of illness and more frequent relapses.To determine the clinical effects of antidepressant medication (...) for the treatment of depression in people who also suffer with schizophrenia.We undertook electronic searches of the Cochrane Schizophrenia Group's Register (October 2000), ClinPsych (1988-2000), The Cochrane Library (Issue 3, 2000), EMBASE (1980-2000) and MEDLINE (1966-2000). This was supplemented by citation searching, personal contact with authors and pharmaceutical companies.All randomised clinical trials that compared antidepressant medication with placebo for people with schizophrenia or schizoaffective

2002 Cochrane

503. Haloperidol dose for the acute phase of schizophrenia. (Abstract)

Haloperidol dose for the acute phase of schizophrenia. Haloperidol is a benchmark, accessible antipsychotic against which the effects of newer treatments are gauged.The primary goal of this review is to determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia.The reviewers searched Biological Abstracts (1980-1999), CINAHL (1982-1999), The Cochrane Library (1999, Issue 2), The Cochrane Schizophrenia Group's Register (December 1999), EMBASE (...) (1980-1999), MEDLINE (1966-1999) and PsycLIT (1887-1999). They also inspected all references of all identified trials and included studies sought as a citation on SCISEARCH database (1980-1999). Authors of identified studies and pharmaceutical companies were also contacted.Studies were selected if they involved people being treated for acute schizophrenia, randomised to two or more dose ranges of non-depot haloperidol, and if they reported clinically meaningful outcomes.The reviewers independently

2002 Cochrane

504. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care

Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute for Clinical Excellence (NICE) 2002: 62 Authors' objectives For the purposes of this guideline, the treatment and management of schizophrenia has been divided into three phases: - initiation of treatment at the first episode - acute phase

2002 Health Technology Assessment (HTA) Database.

505. An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics

of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clinical Therapeutics 2002; 24(10): 1648-1667 PubMedID Other publications of related interest Emsley RA, Raniwalla J, Bailey PJ, Jones AM, for the PRIZE Study Group. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history and a demonstrated, partial response to conventional antipsychotic treatment. International Clinical (...) An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics Tilden D, Aristides M, Meddis D, Burns T Record Status This is a critical

2002 NHS Economic Evaluation Database.

506. Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic

Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic Hosak L, Bahbouh R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of risperidone versus standard neuroleptics in the treatment of schizophrenia. Standard neuroleptics comprised a combination of chlorpromazine, chlorprothixene, haloperidol, levomepromazine, oxyprothepine, perfenazine and thioridazine. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 65 years

2002 NHS Economic Evaluation Database.

507. Psychological treatments in schizophrenia - II: meta-analyses of randomized controlled trials of social skills training and cognitive remediation

, Orbach G, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol Med 2002;32:763-82. Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Cognitive Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Schizophrenia /therapy; Schizophrenic Psychology; Social Adjustment; Social Behavior Disorders /psychology /therapy AccessionNumber 12002001919 Date (...) Psychological treatments in schizophrenia - II: meta-analyses of randomized controlled trials of social skills training and cognitive remediation Psychological treatments in schizophrenia - II: meta-analyses of randomized controlled trials of social skills training and cognitive remediation Psychological treatments in schizophrenia - II: meta-analyses of randomized controlled trials of social skills training and cognitive remediation Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J

2002 DARE.

508. Psychological treatments in schizophrenia - I: meta-analysis of family intervention and cognitive behaviour therapy

Med 2002;32:783-91. Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Cognitive Therapy; Family Therapy; Humans; Male; Middle Aged; Outcome and Process Assessment (Health Care); Randomized Controlled Trials as Topic; Schizophrenia /therapy; Schizophrenic Psychology AccessionNumber 12002001918 Date bibliographic record published 30/06/2004 Date abstract record published 30/06/2004 Record Status This is a critical abstract of a systematic review that meets the criteria (...) Psychological treatments in schizophrenia - I: meta-analysis of family intervention and cognitive behaviour therapy Psychological treatments in schizophrenia - I: meta-analysis of family intervention and cognitive behaviour therapy Psychological treatments in schizophrenia - I: meta-analysis of family intervention and cognitive behaviour therapy Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, Morgan C Authors' objectives To assess the effect of family interventions (FIs

2002 DARE.

509. Interventions to improve medication adherence in schizophrenia Full Text available with Trip Pro

Interventions to improve medication adherence in schizophrenia Interventions to improve medication adherence in schizophrenia Interventions to improve medication adherence in schizophrenia Zygmunt A, Olfson M, Boyer C A, Mechanic D Authors' objectives To examine psychosocial interventions for improving medication adherence, focusing on promising initiatives, reasonable standards for conducting research in this area, and implications for clinical practice. Searching MEDLINE and PsycLIT were (...) comparing outcomes between two or more groups, not necessarily randomised, were included if they had more than 10 patients. Specific interventions included in the review Studies of interventions to modify adherence to antipsychotic medications were included. The types of interventions in the included studies were individual patient, group, family, community and mixed modality. Participants included in the review Studies in which the majority of the patients had a diagnosis of schizophrenia were included

2002 DARE.

510. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia

was derived from several published studies. The authors also made some assumptions, which were used in the decision model. Modelling A Markov model was constructed to assess the cost-effectiveness of the three treatments for schizophrenia over a period of 5 years. Each cycle in the model lasted 6 months. The 6-month cycle period was justified by the authors on the clinical grounds that, currently, it is accepted that any schizophrenic deterioration that occurs within 6 months of a relapse should (...) A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia Hansen K, Francois C, Toumi M, Lancon C Record Status This is a critical abstract of an economic evaluation that meets

2002 NHS Economic Evaluation Database.

511. The effectiveness of health assessments in primary care as a strategy for improving both physical and mental health in patients with schizophrenic illness

or operating an opportunistic assessment programme for patients with schizophrenic illness in primary care would need to fully evaluate their effectiveness in practice. Project page URL Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Family Practice; Physicians, Family; Primary Health Care; Schizophrenia Language Published English Country of organisation England Address for correspondence Elaena Donald-Lopez, West Midlands Health Technology Assessment Collaboration, Department (...) The effectiveness of health assessments in primary care as a strategy for improving both physical and mental health in patients with schizophrenic illness The effectiveness of health assessments in primary care as a strategy for improving both physical and mental health in patients with schizophrenic illness The effectiveness of health assessments in primary care as a strategy for improving both physical and mental health in patients with schizophrenic illness Roberts L, Gold L, Moore D, Elley

2002 Health Technology Assessment (HTA) Database.

512. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia

Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 43. 2002 Authors' objectives To provide guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Authors' conclusions Guidance: 1.1 The choice of antipsychotic drug should be made jointly by the individual

2002 Health Technology Assessment (HTA) Database.

513. Effect of social class at birth on risk and presentation of schizophrenia: case-control study. Full Text available with Trip Pro

Effect of social class at birth on risk and presentation of schizophrenia: case-control study. To examine if low parental social class increases children's risk of subsequently developing schizophrenia or modifies the presentation.Case-control study with historical controls.Geographically defined region in south Dublin.352 patients with first presentation of schizophrenia matched with the next registered same sex birth from the same birth registration district.Social class at birth. Age (...) at presentation to psychiatric services, admission to hospital, and diagnosis of schizophrenia.Risk of schizophrenia was not increased in people from lower social classes. There was a slight excess risk among people in highest social classes (odds ratio 0.59, 95% confidence interval 0.40 to 0.85). However, the mean age at presentation was 24.8 years for patients whose parents were in the highest social class compared with 33.1 years for those in the lowest social class at birth.Although social class of origin

2001 BMJ

514. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. Full Text available with Trip Pro

Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. To determine whether the incidence of schizophrenia among people from non-white ethnic minorities is greater in neighbourhoods where they constitute a smaller proportion of the total population.Ecological design including retrospective study of case records to calculate the incidence of schizophrenia in the ethnic minority population across electoral wards and multi-level analysis (...) to examine interaction between individuals and environment.15 electoral wards in Camberwell, South London.All people aged 16 years and over who had contact with psychiatric services during 1988-97.Incidence rates of schizophrenia according to Research Diagnostic Criteria.The incidence of schizophrenia in non-white ethnic minorities increased significantly as the proportion of such minorities in the local population fell. The incidence rate ratio varied in a dose-response fashion from 2.38 (95% confidence

2001 BMJ

515. Randomised trial of personalised computer based information for patients with schizophrenia. Full Text available with Trip Pro

Randomised trial of personalised computer based information for patients with schizophrenia. To compare use, effect, and cost of personalised computer education with community psychiatric nurse education for patients with schizophrenia.Randomised trial of three interventions. Modelling of costs of alternatives.112 patients with schizophrenia in contact with community services; 67 completed the intervention.Three interventions of five educational sessions: (a) computer intervention combining (...) information from patient's medical record with general information about schizophrenia; (b) sessions with a community psychiatric nurse; (c) "combination" (first and last sessions with nurse and remainder with computer).Patients' attendance, opinions, change in knowledge, and psychological state; costs of interventions and patients' use of NHS community services; modelling of costs for these three, and alternative, interventions.Rates of completion of intervention did not differ significantly (71

2001 BMJ Controlled trial quality: uncertain

516. Haloperidol versus placebo for schizophrenia. (Abstract)

Haloperidol versus placebo for schizophrenia. Haloperidol was developed in the late 1950s for use in the field of analgesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as an antipsychotic.To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared to placebo.Electronic searches of Biological (...) Abstracts (1985-1998), CINAHL (1982-1998), The Cochrane Library (1998, Issue 4), The Cochrane Schizophrenia Group's Register (December 2000), EMBASE (1980-1998), MEDLINE (1966-1998), PsycLIT (1974-1998), and SCISEARCH (January 1974-December 1998) were undertaken. References of all identified studies were searched for further trial citations. Authors of trials and pharmaceutical companies were contacted for further information and archive material.All relevant randomised controlled trials comparing use

2001 Cochrane

517. Cognitive behavioral therapy for schizophrenia: an empirical review

; Male; Psychotherapy /methods; Randomized Controlled Trials as Topic; Schizophrenia /drug therapy /therapy; Schizophrenic Psychology; Treatment Outcome AccessionNumber 12001001421 Date bibliographic record published 31/01/2003 Date abstract record published 31/01/2003 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed (...) Cognitive behavioral therapy for schizophrenia: an empirical review Cognitive behavioral therapy for schizophrenia: an empirical review Cognitive behavioral therapy for schizophrenia: an empirical review Rector N A, Beck A T Authors' objectives The authors appear to study the effectiveness of cognitive-behavioural therapy (CBT) interventions for patients with a schizophrenia-spectrum disorder. Searching MEDLINE and PsycINFO were searched, although the dates were not specified. The search terms

2001 DARE.

518. Attention training in the cognitive rehabilitation of schizophrenic patients: a review of efficacy studies

the same treatment programme; graphics-based computer games; and viewing of documentaries. The training lasted from 3 to 12 weeks, and the total number of sessions ranged from 6 to 60. Participants included in the review Schizophrenic patients were eligible. There was no a priori definition of schizophrenia. Patients in the review included schizophrenic patients with a first episode, chronic in- and out-patients, chronic paranoid, and undifferentiated schizophrenic in-patients. Outcomes assessed (...) Therapy /methods; Case-Control Studies; Humans; Psychomotor Performance; Schizophrenia /rehabilitation; Schizophrenic Psychology; Treatment Outcome AccessionNumber 12001000469 Date bibliographic record published 30/11/2002 Date abstract record published 30/11/2002 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical

2001 DARE.

519. Training community psychiatric nurses in schizophrenia family work: a study of clinical and economic outcomes for patients and relatives

Training community psychiatric nurses in schizophrenia family work: a study of clinical and economic outcomes for patients and relatives Training community psychiatric nurses in schizophrenia family work: a study of clinical and economic outcomes for patients and relatives Training community psychiatric nurses in schizophrenia family work: a study of clinical and economic outcomes for patients and relatives Leff J, Sharpley M, Chisholm D, Bell R, Gamble C Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology examined was cognitive and behavioural therapies given by community psychiatric nurses to families caring for a person with schizophrenia. The complete package included two educational sessions

2001 NHS Economic Evaluation Database.

520. A comparison of effectiveness and cost between two models of care for individuals with schizophrenia living in Taiwan

A comparison of effectiveness and cost between two models of care for individuals with schizophrenia living in Taiwan A comparison of effectiveness and cost between two models of care for individuals with schizophrenia living in Taiwan A comparison of effectiveness and cost between two models of care for individuals with schizophrenia living in Taiwan Lin E C, Yin T J, Kuo B I, Chang W Y, Tsai S L Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The implementation of a hospital-based home care (HBHC) model to care for schizophrenic patients. The home care model was based on three elements: physical care (including physical assessment, illness and medication education, administering medication through injection, assessment

2001 NHS Economic Evaluation Database.